Short answer: A liposomal formulation brief is a structured document that tells a non-sterile compounding pharmacy exactly what to prepare, for whom, and why a liposomal vehicle is being requested instead of a standard form. It goes beyond a prescription by specifying the active, strength, dosage form, target population, excipient constraints, stability expectations, and clinical rationale for liposomal delivery — giving the pharmacy enough information to assess feasibility and prepare the formulation under Good Compounding Practice (GCP).
Why a liposomal brief needs more detail than a standard prescription
A standard compounding prescription names the patient, active ingredient, strength, and dosage form. A liposomal brief adds a layer: it explains why a phospholipid-encapsulated vehicle is being requested, what the prescriber expects from that delivery form, and what constraints the patient or clinical situation imposes. Without this detail, the pharmacy cannot assess whether a liposomal preparation is practical for the requested active, whether the strength is achievable in a liposomal vehicle, or whether the patient’s excipient sensitivities are compatible with the phospholipid system.
The clinical rationale matters because liposomal delivery is not a universal upgrade. A meta-analysis of phospholipid-based solid drug formulations for oral bioavailability enhancement concluded that phospholipid delivery systems can meaningfully influence oral absorption, but the effect is compound-specific and formulation-dependent rather than guaranteed across all actives (Fong et al., European Journal of Pharmaceutical Sciences, 2015; PMID 26296863). A randomised controlled trial of a novel double-layered nano-liposomal curcumin preparation demonstrated enhanced oral bioavailability compared with a standard formulation, but the result reflects the specific formulation studied, not a general property of all liposomal preparations (Kim et al., Scientific Reports, 2026; PMID 42225688). A separate randomised controlled trial of next-generation liposomal coenzyme Q10 reported improved oral absorption with a metazome-based liposomal system, again tied to a specific formulation design (Amalraj et al., Food & Function, 2026; PMID 41582714).
These studies underline why the brief must state the clinical problem the liposomal vehicle is intended to address — poor oral bioavailability, rapid first-pass metabolism, or gastrointestinal intolerance — rather than simply requesting “liposomal” as a label. The pharmacy needs that rationale to select the appropriate phospholipid system and assess compatibility.
The one-page template: fields every liposomal brief should include
The template below is organised into ten field groups. Copy this structure into a clinic letterhead or electronic referral and fill in each section to give the pharmacy a complete picture in a single document.
1. Patient and prescriber identification
- Patient name (named-patient compounding)
- Patient age and weight
- Known allergies or sensitivities (especially to soy, egg phospholipids, or specific excipients)
- Prescriber name, registration number, clinic, and contact details
2. Clinical indication and rationale
- The clinical reason for prescribing (stated neutrally, without disease claims or promises of efficacy)
- Why compounding is preferred over a commercial product (e.g. strength not available, excipient exclusion)
- Why a liposomal vehicle is being requested rather than a standard form (e.g. poor oral bioavailability, rapid first-pass metabolism, gastrointestinal intolerance)
3. Target population
- Adult or paediatric
- Pregnancy or lactation status if relevant
4. Active ingredient and strength
- Active ingredient name (INN or standard nomenclature)
- Requested strength (e.g. mg per mL for a liquid, mg per capsule)
5. Desired dosage form and route
- Requested form: capsule, liquid (oral liquid or suspension), cream, gel, tonic, or serum
- Whether the liposomal form is required or preferred
- Route of administration (oral, topical)
6. Dosing regimen
- Dose per administration
- Frequency
- Duration of supply requested
7. Excipient preferences and constraints
- Excipient exclusions (e.g. soy lecithin if soy-allergic, alcohol-free if required)
- Flavour preferences for oral liquids (relevant for paediatric or palatability-sensitive patients)
- Any previous product tolerability issues to avoid
8. Stability and expiry expectations
- Requested beyond-use date (BUD) or expected shelf life
- Storage conditions the patient can realistically maintain (refrigerated vs room temperature)
9. Packaging and labelling instructions
- Container preference and volume or quantity to supply
- Labelling requirements (patient name, active, strength, BUD, storage instructions, “keep out of reach of children”)
10. Prescribing and monitoring notes
- Review or follow-up timing
- Parameters to monitor (e.g. symptom diary, laboratory markers if relevant)
- Contact specification for pharmacy queries
Worked example: a completed liposomal brief
The example below illustrates a completed brief for a hypothetical adult patient. It is illustrative only — a real brief reflects the individual patient’s clinical situation and the prescriber’s judgement.
| Field | Completed entry |
|---|---|
| Patient | Adult female, 52 kg, no known allergies |
| Clinical rationale | Active has poor oral bioavailability due to rapid first-pass glucuronidation; standard capsule provides low systemic exposure. Liposomal vehicle requested to address this pharmacokinetic limitation. |
| Active and strength | Resveratrol 250 mg per 5 mL |
| Dosage form | Liposomal oral liquid |
| Dosing | 5 mL once daily, 30-day supply |
| Excipient constraints | No soy lecithin (patient prefers sunflower-based phospholipid); alcohol-free vehicle |
| Stability | Refrigerated storage acceptable; BUD per pharmacy assessment |
| Packaging | Amber glass bottle, 150 mL, child-resistant cap |
| Monitoring | Review at 4 weeks; symptom diary; discontinue if adverse effects |
This detail lets the pharmacy assess whether the requested strength is achievable in a liposomal oral liquid, whether a sunflower-based phospholipid is compatible, and what BUD to assign. The prescriber is requesting a specification, not instructing compounding steps — the pharmacy determines the formulation approach under GCP.
Excipient and stability considerations specific to liposomal preparations
Liposomal formulations introduce excipient and stability variables that standard compounding does not. The phospholipid system — typically lecithin from soy or sunflower — is itself an excipient that can trigger allergies, and the prescriber should flag any soy sensitivity in the brief so the pharmacy can select an alternative phospholipid source. A randomised controlled trial of quercetin phytosome (a phospholipid-based delivery system using food-grade lecithin) demonstrated improved oral absorption of quercetin compared with standard formulation, illustrating that the phospholipid component is functionally significant, not merely a carrier (Riva et al., European Journal of Drug Metabolism and Pharmacokinetics, 2019; PMID 30328058).
Stability is the other key variable. Liposomal preparations may have shorter beyond-use dates because the phospholipid bilayer is affected by temperature, oxidation, and microbial growth in aqueous vehicles. The prescriber should state the storage conditions the patient can maintain — refrigeration is often necessary — and request a BUD rather than assuming a long shelf life. The pharmacy assigns the BUD based on water activity, ingredient stability data, and packaging.
Pre-submission checklist for prescribers
Before sending the brief, confirm each item below is complete — gaps trigger clarification queries that delay preparation.
- Patient name, age, weight, and allergy status are stated
- Clinical rationale for compounding and for liposomal delivery is stated (no disease claims)
- Active ingredient, strength, dosage form, and route are specified
- Dosing regimen and supply duration are stated
- Excipient exclusions and preferences are listed
- Storage conditions, packaging, and labelling requirements are specified
- Monitoring and review plan is included
- Prescriber contact for pharmacy queries is provided
Discussing a liposomal preparation with Lynnity
Lynnity Pharma prepares non-sterile compounded preparations in capsule, liquid (including oral liquids and suspensions), cream, gel, tonic, and serum forms — each available in a liposomal or an ordinary form — for a named patient on a doctor’s prescription under Good Compounding Practice (GCP). A prescriber can send the completed formulation brief together with the prescription, and the pharmacy will assess feasibility, phospholipid compatibility, and stability before confirming the formulation. Where a related preparation is also under consideration — a standard capsule of the same active, or a topical cream or gel for local delivery — the brief can note that alternative, and the pharmacy can advise on which form best matches the clinical intent.
Frequently asked questions
What dosage forms can a liposomal brief request from a non-sterile compounding pharmacy?
A non-sterile compounding pharmacy prepares capsules, oral liquids and suspensions, creams, gels, tonics, and serums — each in a liposomal or an ordinary form. The brief should state the requested form and whether the liposomal version is required or preferred. Forms outside this scope, such as injectable or parenteral preparations, are not within non-sterile compounding and should not be requested.
Should the brief specify the phospholipid type or let the pharmacy decide?
The brief should state any patient-specific constraint — a soy allergy, for example, means a sunflower-based phospholipid is needed. Beyond that, the pharmacy selects the phospholipid system based on the active’s compatibility and stability. The prescriber’s role is to flag constraints and clinical rationale, not to specify the compounding method.
How detailed should the clinical rationale section be?
Two or three sentences are usually sufficient. State the clinical reason for prescribing, why compounding is preferred over a commercial product, and why a liposomal vehicle is being requested. Avoid disease claims or promises of efficacy — the rationale should be a neutral statement of the pharmaceutical problem the liposomal form is intended to address.
What happens if the pharmacy cannot prepare the requested liposomal formulation?
The pharmacy will contact the prescriber to discuss alternatives — a different dosage form, a different strength, or a non-liposomal preparation that may meet the clinical need. The contact specification in the brief ensures this conversation happens promptly rather than the referral being returned without explanation.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
To discuss a patient-specific liposomal preparation or clarify any field in the template above, consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.